|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400092886 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-25 18:20:28 |
|
注册时间: Date of Registration: |
2024-11-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
益生菌辅助治疗婴儿肠绞痛的临床研究 |
|
Public title: |
Clinical study on the assisted treatment of infantile colic with probiotics |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
益生菌治辅助疗婴儿肠绞痛的临床研究 |
|
Scientific title: |
Clinical study on the assisted treatment of infantile colic with probiotics |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨波 |
研究负责人: |
余仁强 |
|
Applicant: |
Bo Yang |
Study leader: |
Renqiang Yu |
|
申请注册联系人电话: Applicant telephone: |
+86 138 6175 3284 |
研究负责人电话: Study leader's telephone: |
+86 150 5067 6990 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
bo.yang@jiangnan.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
yurenqiang553@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省无锡市滨湖区蠡湖大道1800号 |
研究负责人通讯地址: |
江苏省无锡市槐树巷48号 |
|
Applicant address: |
1800, Lihu Avenue, Binhu District, Wuxi, Jiangsu |
Study leader's address: |
48 Huishu Lane, Wuxi, Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
江南大学食品学院 |
||
|
Applicant's institution: |
School of Food Science and Technology, Jiangnan University |
||
|
研究负责人所在单位: |
无锡市妇幼保健院 |
||
|
Affiliation of the Leader: |
Wuxi Maternal and Child Health Care Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-01-1024-25 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
无锡市妇幼保健院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Wuxi Maternal and Child Health Care Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-28 00:00:00 |
||
|
伦理委员会联系人: |
孙琰 |
||
|
Contact Name of the ethic committee: |
Sun Yan |
||
|
伦理委员会联系地址: |
江苏省无锡市槐树巷48号 |
||
|
Contact Address of the ethic committee: |
48 Huishu Lane, Wuxi, Jiangsu |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 139 6167 5310 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
无锡市妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Wuxi Maternal and Child Health Care Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省无锡市梁溪区槐树巷48号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
48 Huishu Lane, Wuxi, Jiangsu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China |
||||||||||||||||||||||
|
Target disease: |
infantile colic |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评估短双歧杆菌CCFM1078、长双歧杆菌婴儿亚种CCFM1269对肠绞痛患儿的有效性;开发有益于肠绞痛患儿病情改善的益生菌菌粉。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy of Bifidobacterium breve CCFM1078 and Bifidobacterium infantis subsp. longum CCFM1269 on infantile colic and to develop a probiotic powder beneficial for the improvement of infantile colic. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)排除器质性病变,诊断符合罗马Ⅳ标准: 1)以临床诊断为目的,必须满足: a.症状起始和停止时婴儿<5月龄; b.无明显诱因而出现长时间的反复哭闹烦躁或易激惹,监护人难以安抚; c.无生长迟缓,发热或疾病的证据。 2)以临床研究为目的,须满足上述3点诊断标准,同时符合以下2项条件: a.研究者通过电话交谈或当面问诊,监护人描述婴儿哭闹或烦躁每天持续3 h或以上,一周至少3 d 或以上; b.24 h内哭闹和烦躁时间达3 h或以上。 (2)男性和女性(0-5个月); (3)入院前未使用过抗生素治疗; (5)近一周未使用任何影响胃肠动力的药物; (6)治疗前血、尿、大便常规,肝、肾功能检查均在正常范围; (7)监护人填写书面知情同意书、基本情况调查表,并在整个实验期间承诺配合研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Excluding organic pathology, the diagnosis meets the criteria of Rome IV: 1) For the purpose of clinical diagnosis, the following criteria must be met: a. The symptoms began and ended before the baby was 5 months old; b. There was no obvious trigger for prolonged recurrent crying, irritability, or agitation that was difficult for the caregiver to soothe; c. There was no evidence of growth delay, fever, or illness. 2) For the purpose of clinical research, the following three diagnostic criteria must be met, in addition to meeting the two conditions below: a. The investigator conducts a telephone interview or in-person consultation, and the caregiver describes the baby's crying or irritability lasting 3 hours or more per day, at least 3 days per week; b. The baby's crying and irritability lasted for 3 hours or more within 24 hours. (2) Males and females aged 0-5 months; (3) No antibiotic treatment prior to admission; (5) No use of any medication affecting gastrointestinal motility within the past week; (6) All blood, urine, and stool routine tests, as well as liver and kidney function tests, are within normal ranges before treatment; (7) The caregiver completes a written informed consent form, a basic information survey form, and agrees to cooperate with the study throughout the trial period. |
||||||||||||||||||||||
|
排除标准: |
(1)急腹症、腹痛型癫痫、肠梗阻、肠套叠等其他疾病所致腹痛; (2)持续性呕吐; (3) 器质性胃肠道疾病(炎症性肠病、腹腔疾病、胃肠道感染、胃肠道出血和胃肠道肿瘤等); (4)合并有恶性肿瘤、先天遗传性疾病等其他疾病; (5)器质性疾病(肝肾心功能不全、糖尿病等); (6)受试者监护人拒绝签署知情同意书,或受试者估计依从性较差,随访依从性差者; (7)在研究开始前4周内使用抗生素、益生菌(酸奶、饮料等)、泻药和其他可能影响肠道功能的药物; (8)对实验益生菌产品的成分过敏或不耐受; (9)有不良反应或严重不良反应、疾病紧急情况、伴随治疗和研究方案违反的受试者将被考虑退出试验。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Abdominal pain caused by acute abdomen, epileptic abdominal pain, intestinal obstruction, intestinal volvulus, and other diseases; (2) Persistent vomiting; (3) Organic gastrointestinal diseases (inflammatory bowel disease, abdominal cavity diseases, gastrointestinal infections, gastrointestinal hemorrhage, and gastrointestinal tumors, etc.); (4) Co-existing malignant tumors, congenital hereditary diseases, and other diseases; (5) Organic disease (liver, kidney, and heart function failure, diabetes, etc.); (6) The guardian of the trial participant refuses to sign the informed consent form, or the trial participant is estimated to have poor compliance, with poor follow-up compliance; (7) The use of antibiotics, probiotics (yogurt, drinks, etc.), laxatives, and other drugs that may affect intestinal function within 4 weeks before the start of the study; (8) Allergic or intolerant to the components of the experimental probiotic product; (9) Participants who experience adverse reactions or serious adverse reactions, have an emergency situation, are receiving concurrent treatment, or violate the study protocol will be considered to withdraw from the trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-11-30 00:00:00至 To 2026-01-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-11-30 00:00:00 至 To 2026-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
在整个研究中按照受试者入选的先后顺序,根据预定的随机方案分配入试验组或对照组。随机方案通过查阅随机对照表或采用计算器或计算机产生。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
In the whole study, the subjects were assigned to the test group or control group according to the predetermined randomization scheme according to the order of selection. The randomization scheme is generated by consulting the randomization control table or using a calculator or computer. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲 |
|
Blinding: |
Double blinded |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
采用NCBI的网上平台公开原始数据https://www.ncbi.nlm.nih.gov/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Open the original data on the NCBI online platform https://www.ncbi.nlm.nih.gov/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病历记录表和电子管理系统对数据进行采集和管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The medical record form and electronic management system are used to collect and manage data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |